仅供参考。不构成财务建议。
Ernexa Therapeutics Inc. Warrants（ERNAW）在 金融服务 行业运营，最新报价为 $0.035，市值为 。
当前关键数据
翻译版分析（2026年4月17日）早于当前英文分析（2026年6月14日），因此不予显示。以下数据与英文页面来自同一数据源。 阅读最新英文分析
- 价格: $0.035 (2026年10月5日)
- 当日涨跌: -9.09%
- 行业板块: 金融服务
ERNAW 的竞争对手是谁？
下表将 ERNAW 与 8 家同行在价格、市值和我们的 AI MoonshotScore 上进行比较。
| 公司 | 价格 | 市值 | MoonshotScore |
|---|---|---|---|
| BMY Bristol-Myers Squibb Company | $58.81 | $125B | 92 |
| AMGN Amgen Inc. | $402.98 | $217B | 84 |
| GILD Gilead Sciences, Inc. | $144.63 | $179B | 65 |
| ICCC ImmuCell Corporation | $9.75 | $88.2M | 77 |
| RLYB Rallybio Corporation | $16.90 | $90.6M | 83 |
| ORMP Oramed Pharmaceuticals Inc. | $4.55 | $186M | 76 |
| ANTX AN2 Therapeutics, Inc. | $5.61 | $202M | 67 |
| NAGE Niagen Bioscience Inc | $2.68 | $213M | 68 |
AI 评分来自 Stock Expert AI · 价格数据：FMP / Yahoo Finance
最新新闻
-
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
Yahoo! Finance: ERNAW News · 5 天前
-
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
Yahoo! Finance: ERNAW News · 6 天前
-
Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors
Yahoo! Finance: ERNAW News · 18 天前
-
Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing
Yahoo! Finance: ERNAW News · 20 天前
数据仅供参考。